MADISON, WIS, May 8, 2017Opsis Therapeutics ('Opsis'), a company developing treatments for retinal diseases, today announced the formation of its scientific advisory board (SAB). Approved by the executive leadership team, the SAB is established to advise on the development and advancement to the clinic of the Opsis pipeline of first-in-class retinal cell therapies.

"We are thrilled to have such talented and experienced scientific advisors providing critical expertise to our team," said David Gamm, M.D. Ph.D., Co-Founder and Chief Scientific Officer (CSO) of Opsis. "Our SAB, composed of renowned experts in retinal disease, is aimed at guiding the company in its scientific and development efforts to advance our cell-based therapies to the clinic. We are delighted to benefit from such invaluable input as we develop our therapeutic pipeline."

The inaugural members of the Opsis SAB include:

  • Kapil Bharti, Ph.D. - Stadtman Investigator, Unit on Ocular Stem Cell & Translational Research, National Eye Institute (NEI), US National Institutes of Health (NIH);

  • Eric A. Pierce, M.D., Ph.D. - Director, Inherited Retinal Disorders Service; Director, Berman-Gund Laboratory for the Study of Retinal Degenerations; Director, Ocular Genomics Institute at Massachusetts Eye and Ear; Solman and Libe Friedman Associate Professor of Ophthalmology at Harvard Medical School;

  • Paul A. Sieving, M.D., Ph.D. - Senior Investigator, National Institutes of Health, Intramural Research Program, Laboratory of Translational Research on Retinal and Macular Degenerations.  Member, National Academy of Medicine, USA.

  • James A. Thomson, Ph.D., DVM - Director of Regenerative Biology, Morgridge Institute for Research; John D. MacArthur Professor of Cell and Regenerative Biology, University of Wisconsin School of Medicine and Public Health; Professor of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara;  Member, National Academy of Sciences (NAS); Co-Founder of Cellular Dynamics International (CDI), a FUJIFILM company;

About Opsis Therapeutics

Opsis Therapeutics is a company focused on discovering and developing new medicines to restore vision to patients suffering from retinal diseases. By combining recent innovations in induced pluripotent cell (iPSC) manufacturing, retinal cell differentiation, functional biomaterials, pre-clinical models of retinal disease, and cell therapeutic delivery techniques, Opsis Therapeutics is developing a comprehensive pipeline of breakthrough treatments targeted at retinal indications. Founded and advised by world experts in retinal disease and cell manufacturing, Opsis Therapeutics partnered with Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, and is headquartered in Madison, Wisconsin. For more information, please visit http://opsistx.com.


FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies.  In the year ended March 31, 2016, the company had global revenues of $22.1 billion, at an exchange rate of 112.54 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.


All product and company names herein may be trademarks of their registered owners.



Lauren Geloso


(914) 789-8303